- •Fingolimod treatment may be associated with VZV vasculopathy in MS patients.
- •Fingolimod related VZV vasculopathy can develop in the absence of prior shingles.
- •Lymphopenia is a risk factor for fingolimod-associated VZV reactivation.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.Neurology. 2012; 79: 2002-2004
- Post-varicella arteriopathy of childhood: natural history of vascular stenosis.Neurology. 2005; 64: 660-663
- Incidence of herpes zoster and associated events including stroke - a population-based cohort study.BMC Infect. Dis. 2015; 15: 488
- The varicella zoster virus vasculopathies: clinical, CSF, imaging and virologic features.Neurology. 2008; 70: 853-860
- High-resolution MRI vessel wall imaging in varicella zoster virus vasculopathy.J. Neurol. Sci. 2015; 351: 168-173
- Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.Mult. Scler. 2014; 20: 471-480
- FYT720 therapy exerts differential effects on T cell subsets in multiple sclerosis.Neurology. 2008; 71: 1261-1267
- Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.JAMA Neurol. 2015; 72: 31-39